

# Intellectual Property Weekly Abstracts Bulletin — Week of September 25, 2017

September 25, 2017

## Patent Decision

FCA allows appeal regarding lack of utility finding in light of Supreme Court's recent decision in Esomeprazole

Bristol-Myers Squibb Canada Co. v. Apotex Inc., 2017 FCA 190

This was an appeal of the Federal Court's ("FC") decision dismissing Bristol-Myers Squibb's ("BMS") prohibition application in respect of its two patents listed against dasatinib (see 2017 FC 296, our summary here). Specifically, the FC held that Apotex's allegations regarding the invalidity of the 932 Patent were justified as BMS failed to establish that all of the promised utilities for claim 27 were demonstrated or soundly predicted as of the relevant date. In respect of the 898 Patent, the FC held that Apotex's allegations regarding invalidity were justified since BMS had failed to establish that the two claims in issue were not obvious and not invalid due to double patenting.

Following the argument of the appeal to the Federal Court of Appeal ("FCA"), the Supreme Court of Canada issued its decision in AstraZeneca Canada Inc v Apotex Inc, 2017 SCC 36 ("Esomeprazole"), "which fundamentally recasts the principles applicable to assessing whether patents meet the utility requirement in section 2 of the Patent Act". The parties were allowed to make post-hearing submissions as to the impact of the Supreme Court's decision on the present appeal.

The FCA held that the FC's determination regarding the lack of utility of claim 27 of the 932 Patent could not stand, and granted the appeal in respect of the 932 Patent. Following the Supreme Court's guidance, the FCA set out the two steps of the test for utility to claim 27 of the 932 Patent: 1) determine the subject-matter of the claim; and 2) determine whether this subject-matter was shown to be useful either by demonstration or sound prediction as of the filing date.

The FCA found that, contrary to what Apotex claimed, the relevant subject-matter of the claim in issue is merely the compound, dasatinib. The FCA also concluded that BMS had demonstrated as of the relevant date that dasatinib had at least a scintilla of utility. As of the filing date, BMS had demonstrated that dasatinib acted to inhibit Src-family protein tyrosine kinases (“PTKs”). **Such demonstration is referred to in the specification of the Patent itself, and confirmed in the evidence of the inventors filed. The FCA also noted that the “discovery of a substance that acted to inhibit certain PTKs represented an important advance and certainly meets the minimal utility requirements that are now applicable following the decision of the Supreme Court in Esomeprazole”.**

**The FCA also dismissed Apotex’s claim that the 932 Patent fails to comply with the requirements of subsection 27(3) of the Patent Act.** This issue was not challenged on appeal. The FCA found that Apotex could not try to raise this issue in its supplemental written submissions, where it was granted leave to only make submissions as to the impact of Esomeprazole on the present issues in dispute.

**The appeal in respect of the 898 Patent was dismissed. The FCA upheld the FC’s finding that claims 1 and 3 of the 898 Patent were obvious. The FCA found it unnecessary to examine the ground of appeal relating to double patenting.**

## Federal Courts Update

The Federal Court issued two Notices: 1) Guideline for Actions under the Amended PMNOC Regulations; and 2) Scheduling Practice for the Hearing of Applications.

## IP Updates

CIPO issued a Practice Notice for Objection Proceedings under Section 11.13 of the Trade-marks Act.

The Canada Border Services Agency (“CBSA”) issued a Customs Notice to indicate that the CBSA accepts information on shipments of counterfeit or pirated goods that are dangerous destined to Canada.

By

[Chantal Saunders, Beverley Moore, Adrian J. Howard](#)

Expertise

[Intellectual Property, Copyright, Licensing, Patents, Trademarks](#)

---

## BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](http://blg.com)

### BLG Offices

#### Calgary

Centennial Place, East Tower  
520 3rd Avenue S.W.  
Calgary, AB, Canada  
T2P 0R3

T 403.232.9500  
F 403.266.1395

#### Ottawa

World Exchange Plaza  
100 Queen Street  
Ottawa, ON, Canada  
K1P 1J9

T 613.237.5160  
F 613.230.8842

#### Vancouver

1200 Waterfront Centre  
200 Burrard Street  
Vancouver, BC, Canada  
V7X 1T2

T 604.687.5744  
F 604.687.1415

#### Montréal

1000 De La Gauchetière Street West  
Suite 900  
Montréal, QC, Canada  
H3B 5H4

T 514.954.2555  
F 514.879.9015

#### Toronto

Bay Adelaide Centre, East Tower  
22 Adelaide Street West  
Toronto, ON, Canada  
M5H 4E3

T 416.367.6000  
F 416.367.6749

The information contained herein is of a general nature and is not intended to constitute legal advice, a complete statement of the law, or an opinion on any subject. No one should act upon it or refrain from acting without a thorough examination of the law after the facts of a specific situation are considered. You are urged to consult your legal adviser in cases of specific questions or concerns. BLG does not warrant or guarantee the accuracy, currency or completeness of this publication. No part of this publication may be reproduced without prior written permission of Borden Ladner Gervais LLP. If this publication was sent to you by BLG and you do not wish to receive further publications from BLG, you may ask to remove your contact information from our mailing lists by emailing [unsubscribe@blg.com](mailto:unsubscribe@blg.com) or manage your subscription preferences at [blg.com/MyPreferences](http://blg.com/MyPreferences). If you feel you have received this message in error please contact [communications@blg.com](mailto:communications@blg.com). BLG's privacy policy for publications may be found at [blg.com/en/privacy](http://blg.com/en/privacy).

© 2024 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.